The Unitary Patent takes another step forward

Par Robert Balsters,

Finally, some good news for the Unitary Patent after the German Federal Constitutional Court rejected the two applications for a preliminary injunction against the German Act of Approval to the Agreement on a Unified Patent Court (UPCA). The decisions mark a key step towards the implementation of the Unitary Patent Convention (UPC), says Robert Balsters.

On 9 July 2021, the German Federal Constitutional Court announced the rejection of two applications for a preliminary injunction against the German Act of Approval to the Agreement on a Unified Patent Court (UPCA).

The latest round of constitutional complaints against Germany's ratification of the UPCA were filed in December 2020 after the German Bundestag and Bundesrat approved the draft law ratifying the Agreement on a Unified Patent Court.

Within touching distance?

Before it can enter into force, the UPCA needs to be ratified by 13 of the 25 participating EU member states, including Germany, France and Italy (Italy replaces the UK following Britain’s exit from the EU). France and Italy have already ratified the agreement, and now the Bundesrat has approved the bill and the latest complaints are overcome, the last step is for the agreement to be signed and formalised by the German President. In theory, this means that it could be possible for the final preparatory steps to set up the Unified Patent Court (UPC) to start later this year.

Although there have been many ups and downs, this time it may be good to start preparing for the launch of the Unitary Patent system.

For more about the Unitary Patent, please see our frequently asked questions.

Robert Balsters is a Patent Attorney at Novagraaf in Geneva.

Insights liés

Articles

Oncologie : l'Europe excelle en stratups mais peine à s'imposer dans l'innovation de pointe

L'Office européen des brevets (OEB) a publié le mois dernier sa deuxième étude en matière d’innovation dans les technologies anticancéreuses. Selon cette étude, l'Europe est en tête en nombre de startups dédiées à l'oncologie mais recule face aux États-Unis et à la Chine dans les domaines technologiques les plus innovants contre le cancer, notamment en immunothérapie cellulaire, thérapie génique et analyse d’images. Par ailleurs, la recherche publique joue un rôle central dans l’innovation oncologique européenne, la France se distinguant particulièrement avec l’INSERM et le CNRS, classés deuxième et troisième mondialement pour les dépôts de brevets liés au cancer.

Par Nadège Lagneau,
Oncologie : l'Europe excelle en stratups mais peine à s'imposer dans l'innovation de pointe

Pour plus d'informations ou de conseils contactez-nous